Sevion Therapeutics Inc., a biopharmaceutical company developing therapies for cancer and immunological diseases, has raised $3.02 million in equity financing according to a recent statement filed with the Securities and Exchange Commission.

Sevion could not immediately be reached for comment. According to the SEC, Sevion filed the new Form D on May 15, 2015, but disclosed that the first date of sale was May 1, 2015.

Sevion is headquartered in La Jolla, and its common shares currently trade on the OTCQB stock exchange under the symbol SVON.